Posted by Michael Wonder on 23 Jun 2021
Orpathys approved in China for patients with lung cancer and MET gene alterations
23 June 2021 - First-in-class approval in China in this setting and first regulatory approval for the oral, potent and highly selective MET tyrosine kinase inhibitor
AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.
